Science is facing a “reproducibility crisis” where more than two-thirds of researchers have tried and failed to reproduce another scientist’s experiments, research suggests.
This is frustrating clinicians and drug developers who want solid foundations of pre-clinical research to build upon.
From his lab at the University of Virginia’s Centre for Open Science, immunologist Dr Tim Errington runs The Reproducibility Project, which attempted to repeat the findings reported in five landmark cancer studies. . . .
After meticulous research involving painstaking attention to detail over several years (the project was launched in 2011), the team was able to confirm only two of the original studies’ findings.
Two more proved inconclusive and in the fifth, the team completely failed to replicate the result. . . .
According to a survey published in the journal Nature last summer, more than 70% of researchers have tried and failed to reproduce another scientist’s experiments. . . .
The reproducibility difficulties are not about fraud, according to Dame Ottoline Leyser, director of the Sainsbury Laboratory at the University of Cambridge.
That would be relatively easy to stamp out. Instead, she says: “It’s about a culture that promotes impact over substance, flashy findings over the dull, confirmatory work that most of science is about.”
She says it’s about the funding bodies that want to secure the biggest bang for their bucks, the peer review journals that vie to publish the most exciting breakthroughs, the institutes and universities that measure success in grants won and papers published and the ambition of the researchers themselves. . . .